Abbott Laboratories chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 24.90
Dividend & Yield2.04$ (2.02%)
Beta 0.65
Market capitalization 181.53B
Operating cash flow 9.58B
ESG Scores 25.0

Company description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Sector: Healthcare - Industry: Medical Devices

Financial Ratios
Quick Ratio1.46
Working Capital0.64
Return On Equity0.2
Debt To Equity0.48
Fixed Asset Ratio0.21
Fixed Interest Cover17.29

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Change To Liabilities 220M 1.77B 1.29B 420M
Total Cashflows From Investing Activities -1.81B -2.21B -2.01B -1.74B
Net Borrowings -1.6B -50M -248M -699M
Total Cash From Financing Activities -4.29B -2.78B -5.49B -7.64B
Change To Operating Activities -138M -627M -312M -75M
Issuance Of Stock 298M 245M 255M 167M
Net Income 3.69B 4.5B 7.07B 6.93B
Change In Cash 16M 2.98B 2.96B 83M
Effect Of Exchange Rate -16M 71M -70M -122M
Total Cash From Operating Activities 6.14B 7.9B 10.53B 9.58B
Depreciation 3.01B 3.33B 3.54B 3.27B
Change To Account Receivables -275M -924M -383M -68M
Other Cashflows From Financing Activities -11M -11M
Change To Netincome 766M 971M 695M 900M
Capital Expenditures -1.64B -2.18B -1.89B -1.78B

Income Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Research Development 2.44B 2.37B 2.74B 2.89B
Income Before Tax 4.08B 4.97B 8.21B 8.31B
Net Income 3.69B 4.5B 7.07B 6.93B
Selling General Administrative 9.54B 9.59B 11.01B 10.84B
Gross Profit 18.67B 19.75B 25.01B 24.58B
Ebit 4.76B 5.67B 9.22B 8.84B
Operating Income 4.76B 5.67B 9.22B 8.84B
Interest Expense -670M -546M -533M -558M
Income Tax Expense 390M 497M 1.14B 1.37B
Total Revenue 31.9B 34.61B 43.08B 43.65B
Cost Of Revenue 13.23B 14.86B 18.07B 19.07B
Total Other Income ExpenseNet -680M -697M -1.01B -530M
Net Income From Continuing Ops 3.69B 4.47B 7.07B 6.93B
Net Income Applicable To Common Shares 3.67B 4.47B 7.04B 6.91B

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Total Liabilities 36.59B 39.55B 39.17B 37.53B
Total Stockholder Equity 31.09B 32.78B 35.8B 36.69B
Other Current Liabilities 950M 1.66B 1.23B 1.36B
Total Assets 67.89B 72.55B 75.2B 74.44B
Common Stock 23.85B 24.14B 24.47B 24.71B
Other Current Assets 148M 90M 292M 412M
Retained Earnings 25.85B 27.63B 31.53B 35.26B
Treasury Stock -18.61B -18.99B -20.2B -23.28B
Cash 3.86B 6.84B 9.8B 9.88B
Total Current Liabilities 10.86B 11.91B 13.11B 15.49B
Other Stockholder Equity -8.46B -8.95B -8.37B -8.05B
Property, Plant, and Equipment 8.97B 10.13B 10.11B 10.28B
Total Current Assets 15.67B 20.44B 24.24B 25.22B
Net Tangible Assets -9.13B -5.74B -168M 3.43B
Net Receivables 5.42B 6.41B 6.49B 6.22B
Accounts Payable 3.25B 3.95B 4.41B 4.61B


Insider Transactions

Here are the insider transactions of stock shares related to Abbott Laboratories:

Filer Name Transaction Text Ownership Date Filer Relation Shares
DALE MICHAEL DSale at price 100.70 per share.D2023-03-01Officer1.21k
WOODGRIFT RANDEL WILLIAMSale at price 100.70 per share.D2023-03-01Officer1.03k
SALVADORI DANIEL GESUA SIVESale at price 100.70 per share.D2023-03-01Officer1.08k
WATKIN JARED LSale at price 100.70 per share.D2023-03-01Officer1.2k
MANNING JOSEPH JSale at price 100.70 per share.D2023-03-01Officer1.34k
WAINER ANDREA FSale at price 100.70 per share.D2023-03-01Officer679
MORELAND MARY KSale at price 100.77 per share.D2023-03-01Officer717
AHLBERG GREGORY ASale at price 100.70 per share.D2023-03-01Officer1.32k
TYLER JULIE L.Sale at price 103.24 per share.D2023-02-22Officer260
DALE MICHAEL DStock Award(Grant) at price 0.00 per share.D2023-02-17Officer9.5k
CAPEK JOHN MStock Award(Grant) at price 0.00 per share.D2023-02-17Officer15.86k
WOODGRIFT RANDEL WILLIAMStock Award(Grant) at price 0.00 per share.D2023-02-17Officer9.5k
EARNHARDT LISA DStock Award(Grant) at price 0.00 per share.D2023-02-17Officer15.86k
ALLEN HUBERT L.Stock Award(Grant) at price 0.00 per share.D2023-02-17Officer18.45k
FUNCK ROBERT E. JR.Stock Award(Grant) at price 0.00 per share.D2023-02-17Officer24.42k
FORD ROBERT BStock Award(Grant) at price 0.00 per share.D2023-02-17Chief Executive Officer70.01k
SALVADORI DANIEL GESUA SIVEStock Award(Grant) at price 0.00 per share.D2023-02-17Officer17.7k
WATKIN JARED LStock Award(Grant) at price 0.00 per share.D2023-02-17Officer11.62k
MANNING JOSEPH JStock Award(Grant) at price 0.00 per share.D2023-02-17Officer15.86k
WAINER ANDREA FStock Award(Grant) at price 0.00 per share.D2023-02-17Officer18.23k
GINASCOL JOHN FStock Award(Grant) at price 0.00 per share.D2023-02-17Officer14.27k
MORELAND MARY KStock Award(Grant) at price 0.00 per share.D2023-02-17Officer12.26k
BOUDREAU PHILIP PStock Award(Grant) at price 0.00 per share.D2023-02-17Officer4.86k
AHLBERG GREGORY AStock Award(Grant) at price 0.00 per share.D2023-02-17Officer9.5k
CALAMARI CHRISTOPHER J.Stock Award(Grant) at price 0.00 per share.D2023-02-17Officer10.56k
MORRONE LOUIS HStock Award(Grant) at price 0.00 per share.D2023-02-17Officer10.56k
TYLER JULIE L.Stock Award(Grant) at price 0.00 per share.D2023-02-17Officer7.92k
MATEUS FERNANDOStock Award(Grant) at price 0.00 per share.D2023-02-17Officer10.56k
KARAM SAMMYSale at price 108.75 per share.D2022-12-29Officer4.2k
GINASCOL JOHN FSale at price 112.32 per share.D2022-12-13Officer11k
STARKS DANIEL JSale at price 97.30 - 98.14 per share.D2022-10-27Director50k
MANNING JOSEPH JSale at price 107.00 per share.D2022-09-08Officer23.01k
MANNING JOSEPH JConversion of Exercise of derivative security at price 44.40 per share.D2022-09-08Officer23.01k
FORD ROBERT BSale at price 105.10 per share.D2022-08-25Chief Executive Officer102.42k
FORD ROBERT BConversion of Exercise of derivative security at price 39.12 - 41.14 per share.D2022-08-25Chief Executive Officer102.42k
MANNING JOSEPH JSale at price 104.99 - 105.24 per share.D2022-08-25Officer26.9k
MANNING JOSEPH JConversion of Exercise of derivative security at price 44.40 per share.D2022-08-25Officer23.01k
STARKS DANIEL JSale at price 108.77 - 109.60 per share.D2022-07-26Director50k
MATEUS FERNANDOSale at price 109.05 per share.D2022-07-26Officer2.46k
TYLER JULIE L.Sale at price 109.09 per share.D2022-07-25Officer253
WOODGRIFT RANDEL WILLIAMSale at price 113.00 per share.D2022-05-04Officer24k
WOODGRIFT RANDEL WILLIAMConversion of Exercise of derivative security at price 44.40 per share.D2022-05-04Officer24k
STARKS DANIEL JSale at price 112.51 - 114.84 per share.D2022-05-03Director50k
OSBORN WILLIAM AStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.6k
STARKS DANIEL JStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.6k
TILTON GLENN FLETCHERStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.6k
MCKINSTRY NANCYStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.6k
STRATTON JOHN GStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.6k
ALPERN ROBERT JStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.6k
BLOUNT SALLY EStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.6k
ROMAN MICHAEL FStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.6k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Abbott Laboratories. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Abbott Laboratories

Here is the result of two systematic investment strategies applied to Abbott Laboratories. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Abbott Laboratories

The following chart shows the equity curve of the two systematic investment strategies applied to Abbott Laboratories:

Abbott Laboratories automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 44.49% on the backtest period.

Performance at glance

Performance

44.49 %

Latent gain

995.63 $

Invested capital

2237.99 $

Annualized return

10.75 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Abbott Laboratories

This is the result of two momentum investment strategies applied to Abbott Laboratories. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Abbott Laboratories

The following chart shows all the entries opened by the momentum investment system on Abbott Laboratories:

Abbott Laboratories momentum entries
  • The first momentum investment strategy would give 64.86% of return on Abbott Laboratories. That represents 3816.44$ of latent gain with 5884.42$ of employed capital.
  • The second momentum investment strategy would give 64.1% of return on Abbott Laboratories. That represents 2623.41$ of latent gain with 4092.57$ of employed capital.
Performance at glance (1Q Momentum)

Performance

64.86 %

Latent gain

3816.44 $

Invested capital

5884.42 $

Annualized return

5.17 %
Performance at glance (2Q Momentum)

Performance

64.1 %

Latent gain

2623.41 $

Invested capital

4092.57 $

Annualized return

17.51 %

Momentum equity curve on Abbott Laboratories

The following chart shows the equity curve of the two momentum strategies applied to Abbott Laboratories:

Abbott Laboratories momentum equity

Note: the dividends potentially given by Abbott Laboratories are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Abbott Laboratories

The following chart shows the employed capital evolution of the two momentum strategies on Abbott Laboratories since the beginning:

Abbott Laboratories

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Abbott Laboratories

Buy the dip entry openings on Abbott Laboratories

Abbott Laboratories

The performance achieved by the robo-advisor on Abbott Laboratories is 11.07%. That represents 74.4$ of latent gain with 671.82$ of employed capital. The following chart shows Abbott Laboratories stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Abbott Laboratories, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

11.07 %

Latent gain

74.4 $

Invested capital

671.82 $

Annualized return

5.17 %

Equity curve of the strategy applied to Abbott Laboratories

The following chart shows the result of the investment strategy applied to Abbott Laboratories:

Abbott Laboratories

Note: the dividends potentially given by Abbott Laboratories are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Abbott Laboratories

The following chart shows the employed capital evolution since the beginning of the investment strategy on Abbott Laboratories:

Abbott Laboratories

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Abbott Laboratories

In this section, I will compare the three previous investment strategies applied to Abbott Laboratories.

Equity curve comparison on Abbott Laboratories

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Abbott Laboratories investment strategy comparison

Employed capital comparison on Abbott Laboratories

Abbott Laboratories investment comparison

Performance comparison on Abbott Laboratories

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 44.49% 995.63$ 2237.99$ 10.75%
Momentum 1 quarter 64.86% 3816.44$ 5884.42$ 16.63%
Momentum 2 quarters 64.1% 2623.41$ 4092.57$ 17.51%
Non-directional 11.07% 74.4$ 671.82$ 5.17%
Annualized return comparison

Automatic investment

10.75 %

Momentum 1Q

17.51 %

Momentum 2Q

17.51 %

Non-directional

5.17 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Abbott Laboratories:

Note: The algorithm computes the probability of correlation between Abbott Laboratories and the other stocks. There may be false positives or some missing correlated stocks. If the price of Abbott Laboratories does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Abbott Laboratories
Country United States
City North Chicago
Address 100 Abbott Park Road
Phone 224 667 6100
Website www.abbott.com
FullTime employees 115000
Industry Medical Devices
Sector Healthcare
Exchange XNYS
Ticker ABT
Market www.nyse.com

Abbott Laboratories ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 3.0
Peer Environment Performance 2.2440350877193
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 13.6
Peer Social Performance 12.085087719298
Social Percentile unknown
Highest Controversy 3
Peer Highest Controversy Performance 1.9310344827586
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic yes
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Customer Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 8.4
Peer Governance Performance 7.7398245614035
Governance Percentile unknown

ESG at glance
Total ESG Scores: 25.0
Environment Score: 3.0
Social Score: 13.6
Governance Score: 8.4

ESG Performance: AVG_PERF

Peer Group: Healthcare

Peer Esg Score Performance: 22.091551724138

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 44